Clinical importance of the CYP2C19*17 variant allele for voriconazole
Open Access
- 14 September 2010
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (1), 137-138
- https://doi.org/10.1111/j.1365-2125.2010.03801.x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Voriconazole concentrations and outcome of invasive fungal infectionsClinical Microbiology & Infection, 2010
- Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17British Journal of Clinical Pharmacology, 2010
- Voriconazole therapeutic drug monitoring: focus on safetyExpert Opinion on Drug Safety, 2009
- CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of VoriconazoleThe Journal of Clinical Pharmacology, 2009
- The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteersEuropean Journal of Clinical Pharmacology, 2008
- Therapeutic Drug Monitoring of VoriconazoleTherapeutic Drug Monitoring, 2008
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety OutcomesClinical Infectious Diseases, 2008
- Pharmacokinetic/Pharmacodynamic Profile of VoriconazoleClinical Pharmacokinetics, 2006
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002